Abstract:The nucleotide-binding, oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is a multiprotein complex that combines sensing, regulation, and effector functions to regulate inflammation in health and disease. NLRP3 is activated by a diverse range of inflammation-instigating signals known as pathogen associated molecular patterns and danger associated molecular patterns. Upon activation, NLRP3 oligomerizes and recruits partner proteins to form a supramolecular platform to process the maturation and release of interleukin (IL)-1 β , IL-18, and gasdermin D, major mediators of inflammation and inflammatory cell death termed pyroptosis. The NLRP3 inflammasome has been implicated in the pathogenesis of a wide range of disease conditions, including chronic inflammatory disease that are associated with lifestyle and dietary changes, aging, and environmental exposures, and have become the leading cause of death worldwide. Pharmacological targeting of NLRP3 and signaling demonstrated promising efficacy in ameliorating a list of disease conditions in animal models. These findings underscore the potential and importance of NLRP3 as a druggable target for treating a range of diseases. In this review, recent progress in understanding the structure and mechanism of action of the NLRP3 inflammasome is discussed with focus on pharmacological inhibition of NLRP3 by small molecule inhibitors. New structural and mechanistic insights into NLRP3 activation and inhibitor-NLRP3 interactions would aid in the rational design and pharmacological evaluation of NLRP3 inhibitors for treatment of human disease. Significance Statement The NLRP3 inflammasome plays central role in innate immune sensing and control of inflammation. Pharmacological inhibition of NLRP3 demonstrated promising efficacy in a range of diseases in animal models. Recent elucidation of the structure and inhibitor binding of NLRP3 generated new insights into its mode of action and inhibitor-NLRP3 interaction at molecular levels, providing new framework for developing small chemical inhibitors of NLRP3 with improved efficacy and specificity against chronic disease that has become major health concerns worldwide.

Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential

Progress on the Study of NLRP3 Inflammasome in Autoinflammatory Diseases of Children

Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review)

Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction

NLRP3 inflammasome and its inhibitors: a review

The research progression of direct NLRP3 inhibitors to treat inflammatory disorders

Pharmacological Inhibitors of the NLRP3 Inflammasome

Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors

Specific Nlrp3 Inflammasome Inhibitors: Promising Therapeutic Agents For Inflammatory Diseases

Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases

The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors

Potential Impact of Bioactive Compounds as NLRP3 Inflammasome Inhibitors: An Update

Mechanisms of NLRP3 inflammasome activation and the development of peptide inhibitors

New Potentiality of Bioactive Substances: Regulating the NLRP3 Inflammasome in Autoimmune Diseases

Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases

The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases

NLRP3 inflammasome and its role in autoimmune diseases: A promising therapeutic target

Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease

[Advances in Mechanisms for NLRP3 Inflammasomes Regulation].

NLRP1 inflammasome in neurodegenerative disorders: From pathology to therapies